22101 - Ph3 Imlun vs Endo ER+ HER2- BC

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Disease Types: Breast,&nbs

Available at: {clinical_trial_location backspace="7"}22101 - Ph3 Imlun vs Endo ER+ HER2- BC, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}